bluuebunny/crossref_metadata_2025_split huggingface dataset:
The study of temperature regimes of a pipe wall under turbulent regime and supercritical pressures
Authors: Mammadova J. P. , Abdullaev A. P. , Rzayev R. M. , Kelbaliev R. F. , Mammadova S. H. , Musazade I. V. 
Published: July 2020

The flow regimes of liquids encountered in engineering practice are mainly turbulent due to their structure, with which the features of such flows at supercritical pressure are considered in the work and some results are compared with similar ones obtained at low Reynolds numbers. Under these conditions, the physical properties of the fluid change sharply in the parietal layer and, depending on the values of the heat flux density and temperature, the area of sharp changes in physical properties can move along the flow cross section. Depending on the influence of these factors, the nature of the fluid flow can change, which affects the patterns of heat transfer and, accordingly, the nature of the distribution of wall temperature. In particular, conditions were identified for the appearance of a primary and secondary improved heat transfer regime. The possibility of the existence of an anomalous behavior of heat transfer during a turbulent flow of aromatic hydrocarbons was revealed, the nature of the distribution of the wall temperature along the length of the experimental tube is examined, and the influence of changes in the thermophysical properties of the substance on it is analyzed. The experimental data for water and toluene with a deteriorated heat transfer mode deviate from the calculated by [Formula: see text]25%. As is known, the flow regime of fluids in engineering practice is mainly turbulent in structure. Therefore, it is very important to study the characteristics of such flows at supercritical pressure and compare some results with similar results obtained at low Reynolds numbers.
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer
Authors: Lu Yen-Shen , Lee Keun Seok , Chao Tsu-Yi , Tseng Ling-Ming , Chitapanarux Imjai , Chen Shin-Cheh , Liu Chien-Ting , Sohn Joohyuk , Kim Jee Hyun , Chang Yuan-Ching , Yang Youngsen , Shotelersuk Kanjana , Jung Kyung Hae , Valenti Roberta , Slader Cassandra , Gao Melissa , Park Yeon Hee 
Published: July 2020

Abstract

Purpose:
This study reports the MTD, recommended phase 2 dose (RP2D), and preliminary efficacy of alpelisib or buparlisib used in combination with tamoxifen plus goserelin in premenopausal patients with hormone receptor–positive (HR+), HER2-negative (HER2−) advanced breast cancer (ABC).

Patients and Methods:
This study enrolled premenopausal women with HR+, HER2− ABC. Patients received tamoxifen (20 mg once daily) and goserelin acetate (3.6 mg every 28 days) with either alpelisib (350 mg once daily; n = 16) or buparlisib (100 mg once daily; n = 13) in 28-day cycles until MTD was observed.

Results:
The criteria for MTD were not met for both alpelisib and buparlisib. The RP2D of alpelisib and buparlisib in combination with tamoxifen and goserelin were 350 mg and 100 mg, respectively. Both combinations met protocol-specified criteria for tolerability. The most common grade 3/4 treatment-emergent adverse events (TEAE) were hypokalemia (12.5%), hyperglycemia (6.3%), and rash (6.3%) for alpelisib and alanine aminotransferase increase (30.8%), aspartate aminotransferase increase (23.1%), and anxiety (15.4%) for buparlisib. TEAEs led to treatment discontinuation in 18.8% and 53.8% of alpelisib- and buparlisib-treated patients, respectively. Progression-free survival was 25.2 months in the alpelisib group and 20.6 months in the buparlisib group.

Conclusions:
The RP2Ds of alpelisib and buparlisib were 350 mg and 100 mg, respectively. No unexpected safety findings were reported. Although an early-phase study, data suggest that alpelisib plus endocrine therapy may be a potentially efficacious treatment that warrants further evaluation for premenopausal patients with HR+, HER2− ABC.
See related commentary by Clark et al., p. 371
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
Authors: Batich Kristen A. , Mitchell Duane A. , Healy Patrick , Herndon James E. , Sampson John H. 
Published: July 2020

Abstract
Despite standard of care for glioblastoma, including gross total resection, high-dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this diagnosis compared with more common solid tumors in clinical trials commits new glioblastoma therapies to testing in small, underpowered, nonrandomized settings. Among approximately 200 registered glioblastoma trials identified between 2005 and 2015, nearly half were single-arm studies with sample sizes not exceeding 50 patients. These constraints have made demonstrating efficacy for novel therapies difficult in glioblastoma and other rare and aggressive cancers. Novel immunotherapies for glioblastoma such as vaccination with dendritic cells (DC) have yielded mixed results in clinical trials. To address limited numbers, we sequentially conducted three separate clinical trials utilizing cytomegalovirus (CMV)-specific DC vaccines in patients with newly diagnosed glioblastoma whereby each follow-up study had nearly doubled in sample size. Follow-up data from the first blinded, randomized phase II clinical trial (NCT00639639) revealed that nearly one third of this cohort is without tumor recurrence at 5 years from diagnosis. A second clinical trial (NCT00639639) resulted in a 36% survival rate at 5 years from diagnosis. Results of the first two-arm trial (NCT00639639) showed increased migration of the DC vaccine to draining lymph nodes, and this increased migration has been recapitulated in our larger confirmatory clinical study (NCT02366728). We have now observed that nearly one third of the glioblastoma study patient population receiving CMV-specific DC vaccines results in exceptional long-term survivors.
Effect of Low-dose and Standard-dose Aspirin on PGE2 Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial
Authors: Drew David A. , Schuck Madeline M. , Magicheva-Gupta Marina V. , Stewart Kathleen O. , Gilpin Katherine K. , Miller Patrick , Parziale Melanie P. , Pond Emily N. , Takacsi-Nagy Oliver , Zerjav Dylan C. , Chin Samantha M. , Mackinnon Krems Jennifer , Meixell Dana , Joshi Amit D. , Ma Wenjie , Colizzo Francis P. , Carolan Peter J. , Nishioka Norman S. , Staller Kyle , Richter James M. , Khalili Hamed , Gala Manish K. , Garber John J. , Chung Daniel C. , Yarze Joseph C. , Zukerberg Lawrence , Petrucci Giovanna , Rocca Bianca , Patrono Carlo , Milne Ginger L. , Wang Molin , Chan Andrew T. 
Published: July 2020

Abstract
Low-dose aspirin is recommended by the U.S. Preventive Services Task Force for primary prevention of colorectal cancer in certain individuals. However, broader implementation will require improved precision prevention approaches to identify those most likely to benefit. The major urinary metabolite of PGE2, 11α-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid (PGE-M), is a biomarker for colorectal cancer risk, but it is unknown whether PGE-M is modifiable by aspirin in individuals at risk for colorectal cancer. Adults (N = 180) who recently underwent adenoma resection and did not regularly use aspirin or NSAIDs were recruited to a double-blind, placebo-controlled, randomized trial of aspirin at 81 or 325 mg/day for 8–12 weeks. The primary outcome was postintervention change in urinary PGE-M as measured by LC/MS. A total of 169 participants provided paired urine samples for analysis. Baseline PGE-M excretion was 15.9 ± 14.6 (mean ± S.D, ng/mg creatinine). Aspirin significantly reduced PGE-M excretion (−4.7 ± 14.8) compared with no decrease (0.8 ± 11.8) in the placebo group (P = 0.015; mean duration of treatment = 68.9 days). Aspirin significantly reduced PGE-M levels in participants receiving either 81 (−15%; P = 0.018) or 325 mg/day (−28%; P &lt; 0.0001) compared with placebo. In 40% and 50% of the individuals randomized to 81 or 325 mg/day aspirin, respectively, PGE-M reduction reached a threshold expected to prevent recurrence in 10% of individuals. These results support that aspirin significantly reduces elevated levels of PGE-M in those at increased colorectal cancer risk to levels consistent with lower risk for recurrent neoplasia and underscore the potential utility of PGE-M as a precision chemoprevention biomarker. The ASPIRED trial is registered as NCT02394769.
The Meridional Shift of the Midlatitude Westerlies over Arid Central Asia during the Past 21 000 Years Based on the TraCE-21ka Simulations
Authors: Jiang Nanxuan , Yan Qing , Xu Zhiqing , Shi Jian , Zhang Ran 
Published: July 2020

AbstractTo advance our knowledge of the response of midlatitude westerlies to various external forcings, we investigate the meridional shift of midlatitude westerlies over arid central Asia (ACA) during the past 21 000 years, which experienced more varied forcings than the present day based on a set of transient simulations. Our results suggest that the evolution of midlatitude westerlies over ACA and driving factors vary with time and across seasons. In spring, the location of midlatitude westerlies over ACA oscillates largely during the last deglaciation, driven by meltwater fluxes and continental ice sheets, and then shows a long-term equatorward shift during the Holocene controlled by orbital insolation. In summer, orbital insolation dominates the meridional shift of midlatitude westerlies, with poleward and equatorward migration during the last deglaciation and the Holocene, respectively. From a thermodynamic perspective, variations in zonal winds are linked with the meridional temperature gradient based on the thermal wind relationship. From a dynamic perspective, variations in midlatitude westerlies are mainly induced by anomalous sea surface temperatures over the Indian Ocean through the Matsuno–Gill response and over the North Atlantic Ocean by the propagation of Rossby waves, or both, but their relative importance varies across forcings. Additionally, the modeled meridional shift of midlatitude westerlies is broadly consistent with geological evidence, although model–data discrepancies still exist. Overall, our study provides a possible scenario for a meridional shift of midlatitude westerlies over ACA in response to various external forcings during the past 21 000 years and highlights important roles of both the Indian Ocean and the North Atlantic Ocean in regulating Asian westerlies, which may shed light on the behavior of westerlies in the future.
Spatial Patterns of Human Thermal Comfort Conditions in Russia: Present Climate and Trends
Authors: Varentsov Mikhail , Shartova Natalia , Grischenko Mikhail , Konstantinov Pavel 
Published: July 2020

AbstractThe assessment of bioclimatic conditions at the national scale remains a highly relevant task. It might be one of the main parts of the national strategy for the sustainable development of different regions under changing climatic conditions. This study evaluated the thermal comfort conditions and their changes in Russia according to gridded meteorological data from ERA-Interim reanalysis with a spatial resolution of 0.75° × 0.75° using the two most popular bioclimatic indices based on the human energy balance: physiologically equivalent temperature (PET) and universal thermal comfort index (UTCI). We analyzed the summer and winter means of these indices as well as the repeatability of different thermal stress grades for the current climatological standard normal period (1981–2010) and the trends of these parameters over the 1979–2018 period. We revealed the high diversity of the analyzed parameters in Russia as well as significant differences between the contemporary climate conditions and their changes in terms of mean temperature, mean values of bioclimatic indices, and thermal stress repeatability. Within the country, all degrees of thermal stress were possible; however, severe summer heat stress was rare, and in winter nearly the whole country experienced severe cold stress. Multidirectional changes in bioclimatic conditions were observed in Russia against the general background of climate warming. The European part of the country was most susceptible to climate change because it experiences significant changes both in summer and winter thermal stress repeatability. Intense Arctic warming was not reflected in significant changes in thermal stress repeatability.
Arterial Oxygenation in Traumatic Brain Injury—Relation to Cerebral Energy Metabolism, Autoregulation, and Clinical Outcome
Authors: Wettervik Teodor Svedung , Engquist Henrik , Howells Timothy , Lenell Samuel , Rostami Elham , Hillered Lars , Enblad Per , Lewén Anders 
Published: July 2020

Background: Ischemic and hypoxic secondary brain insults are common and detrimental in traumatic brain injury (TBI). Treatment aims to maintain an adequate cerebral blood flow with sufficient arterial oxygen content. It has been suggested that arterial hyperoxia may be beneficial to the injured brain to compensate for cerebral ischemia, overcome diffusion barriers, and improve mitochondrial function. In this study, we investigated the relation between arterial oxygen levels and cerebral energy metabolism, pressure autoregulation, and clinical outcome. Methods: This retrospective study was based on 115 patients with severe TBI treated in the neurointensive care unit, Uppsala university hospital, Sweden, 2008 to 2018. Data from cerebral microdialysis (MD), arterial blood gases, hemodynamics, and intracranial pressure were analyzed the first 10 days post-injury. The first day post-injury was studied in particular. Results: Arterial oxygen levels were higher and with greater variability on the first day post-injury, whereas it was more stable the following 9 days. Normal-to-high mean pO2 was significantly associated with better pressure autoregulation/lower pressure reactivity index ( P = .02) and lower cerebral MD-lactate ( P = .04) on day 1. Patients with limited cerebral energy metabolic substrate supply (MD-pyruvate below 120 µM) and metabolic disturbances with MD-lactate-/pyruvate ratio (LPR) above 25 had significantly lower arterial oxygen levels than those with limited MD-pyruvate supply and normal MD-LPR ( P = .001) this day. Arterial oxygenation was not associated with clinical outcome. Conclusions: Maintaining a pO2 above 12 kPa and higher may improve oxidative cerebral energy metabolism and pressure autoregulation, particularly in cases of limited energy substrate supply in the early phase of TBI. Evaluating the cerebral energy metabolic profile could yield a better patient selection for hyperoxic treatment in future trials.
A Clinical Review of Biosimilars Approved in Oncology
Authors: Ngo Dat , Chen Jason 
Published: July 2020

Objective To summarize and review the clinical data of Food and Drug Administration (FDA)-approved biosimilars for use in treatment of cancer and the current challenges health care institutions face when implementing a newly approved biosimilar. Data Sources A literature search of the following databases was performed between January 1, 2012, and December 31, 2019: PubMed, Google, and ClinicalTrials.gov. Search terms included the words biosimilar, bevacizumab, rituximab, and/or trastuzumab. Study Selection and Data Extraction Only primary literature on biosimilars with an ongoing or completed phase 3 trial and/or FDA approval were included in the final analysis. Primary literature consisted of peer-reviewed publications, published abstracts, and any results posted on the ClinicalTrials.gov database. Data Synthesis Clinical trials of FDA-approved biosimilars for bevacizumab, rituximab, and trastuzumab showed no significant differences with respect to efficacy, safety, and pharmacokinetics when compared with their reference products. Relevance to Patient Care and Clinical Practice The anticipated growth of biologics in oncology and the recent introduction of biosimilars over the past few years have placed a lot of emphasis on biosimilars as a significant source of cost savings for the health care system. Our article compiles and analyzes existing data on biosimilar efficacy, safety, and financial impact. Conclusions The major concerns of biosimilars revolve around their long-term efficacy and safety. Even with many questions to be answered, biosimilars have the potential for significant cost savings in the US health care system.
Mortality following surgery for geriatric hip fractures: is it the timing or the co-morbidities?
Authors: Yaacobi Eyal , Marom Omer , Gutman Nadav , Zabarqa Shatha , Brin Yaron , Ohana Nissim 
Published: July 2020

Background: Hip fractures are prevalent in the elderly population and present serious health, social and economic problems, with an impact on morbidity and mortality. Today, it is common practice to surgically repair these fractures as early as possible, preferably within 48 hours of hospital admission. However, there is conflicting evidence in the literature about the effect of the timing of surgery on postoperative mortality. Objectives: To assess the association between surgery delay and other demographic and clinical variables with an increased mortality rate after surgical treatment of hip fractures in the elderly. Methods: A retrospective study was conducted on patients aged ⩾65 years with a primary diagnosis of hip fracture. All patients underwent surgery in our Medical Center from 2015 to 2017. A multivariate model of logistic regression, Cox regression model and Kaplan-Meier survival analysis were used to evaluate the relationship between various variables and mortality rates at 3- and 12-month follow-ups. Results: A total of 877 patients were included, 30% were men and 70% women; the mean age was 83.3 years. Multivariate analysis showed that mortality was significantly higher among patients who underwent late surgery, after adjusting for gender, age, co-morbidity, age of surgeon, duration of surgery and duration of hospitalisation ( p = 0.030). Surgical delay was significantly associated with higher mortality rates both at 3 month ( p = 0.041) and at 12 months after surgery ( p = 0.013). The presence of ischemic heart disease, congestive heart failure, paroxysmal atrial fibrillation and chronic renal failure, as well as male gender and older age, were also significantly associated with higher early and late mortality. Conclusions: In elderly patients, hip fracture surgery should be performed within 48 hours of admission. Male and older patients, as well as patients with the aforementioned co-morbidities, are at higher risk of mortality at 3 and 12 months after surgery.
Chemokine-like factor 1: A promising therapeutic target in human diseases
Authors: Cai Xiaopeng , Deng Jingwen , Ming Qianqian , Cai Huiqiang , Chen Zhi 
Published: July 2020

Chemokines are a family of small molecular-weight proteins, being well-known with their important roles in the process of allergic response, immune regulation, cell proliferation, and differentiation. Almost two decades ago, a novel member of this family, chemokine-like factor 1 (CKLF1) was identified. In recent years, it draws much attention of researchers because of its key roles in many types of tissues and its potential implications in a large number of diseases. Up to now, CKLF1 has been shown to have two main functions: broad-spectrum chemotactic activity, and proliferation- and differentiation-promoting abilities. In this review, we would introduce the basic structural features of CKLF1 and its biological functions, and then elaborate the relationships between CKLF1 and human diseases. The cell signaling pathways CKLF1 may be involved in would be discussed and summarized in details. Furthermore, we present the trials of CKLF1-targeted treatments in animal disease models, hoping to provide a few important insights about CKLF1 to both medical researchers and pharmacy, and finally conclude that CKLF1 is a potent, and very promising, therapeutic target. Impact statement CKLF1, a recently identified chemokine, has been reported by a number of studies to play important roles in quite many diseases. However, the potential pathways that CKLF1 may be involved are not manifested well yet. In our review, we showed the basic molecular structure and major functions of this novel chemokine, and implication in human diseases, such as tumors. To attract more attention, we summarized its signaling pathways and clearly present them in a set of figures. With the overview of the experimental trial of CKLF1-targeting medicines in animal models, we hope to provide a few important insights about CKLF1 to both medical researchers and pharmacy.
Outcomes of rheolytic thrombectomy in phlegmasia cerulea dolens
Authors: Saydam Onur , Serefli Deniz 
Published: July 2020

Objective The purpose of this study was to assess the clinical features of phlegmasia cerulea dolens and present the treatment outcomes with rheolytic thrombectomy device. Methods From January 2014 and March 2019, 329 patients were diagnosed and hospitalized for acute iliofemoral deep vein thrombosis, and among those patients, seven patients diagnosed with lower extremity phlegmasia cerulea dolens were consecutively enrolled. Diagnosis of phlegmasia cerulea dolens was initially made on clinical findings followed by imaging with Doppler ultrasound. The rheolytic thrombectomy device was used in all patients with a combination of catheter-directed thrombolysis as an adjunctive therapy to facilitate more rapid thrombus clearance except for one patient who had a contraindication to the use of tissue plasminogen activator. Results Seven patients (four men, three women; median age, 63 years, range 52–68 years) were included. One patient had a relative contradiction to thrombolysis due to history of coronary artery bypass graft surgery; all other patients underwent pharmaco-mechanical thrombectomy with power pulse mode. The upper limit of 480 s was completed in all patients, and this time was not exceeded to prevent hemolysis-related complications. Six Fr catheters were used in four (57.1%) patients, and 8 Fr catheters were used in three patients (42.9%). Mean thrombolytic infusion duration was 28 ± 6.2 h for patients who received tissue plasminogen activator. After catheter-directed thrombolysis, total radiological success was achieved in two patients, and partial radiologic success was achieved in five patients; however, in all seven patients, clinical success was achieved. The mean duration for complete regression of cyanosis was 18.9 ± 8.1 h. Although no patients required blood replacement, mean decreases in hemoglobin and hematocrit were 2.7 ± 1.37 g/dl and 6.42 ± 4.47%, respectively. Acute kidney injury developed in three patients (42.9%). One patient required continuous renal replacement therapy. No cardiac complication was observed. One (14.3%) patient died of ventilator-related pneumonia on postprocedural day 10. The median duration of intensive care unit stay and hospital stay were 72 h (min–max: 24–264 h) and six days (min–max: 5–33 days), respectively. Conclusion Rheolytic thrombectomy was less invasive and effective strategy for early stage phlegmasia cerulea dolens at creating rapid thrombus clearance to establish clinical success and facilitate more conservative management with catheter-directed thrombolysis.